About us Contacts Drug interactions: 390 212
Drug search by name

Celexa (Citalopram Tablets) and Clozaril

Determining the interaction of Celexa (Citalopram Tablets) and Clozaril and the possibility of their joint administration.

Check result:
Celexa (Citalopram Tablets) <> Clozaril
Relevance: 11.02.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using cloZAPine together with citalopram. Combining these medications can increase the risk of an irregular heart rhythm that may be serious. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or special monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as clozapine may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In a randomized, double-blind, crossover, escalating multiple-dose study consisting of 119 healthy subjects, the maximum mean increase in corrected QT interval from placebo was 8.5 msec for citalopram 20 mg and 18.5 msec for citalopram 60 mg. Based on the established exposure-response relationship, prolongation of the corrected QT interval was estimated to be 12.6 ms for citalopram 40 mg. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 40 mg/day. Studies have not shown a benefit in the treatment of depression at dosages above 40 mg/day. Hypokalemia and hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. ECG monitoring is recommended with concomitant medications that have demonstrated prolongation of the QT interval and/or underlying risk factors such as heart failure or bradyarrhythmia. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.

MONITOR CLOSELY: Coadministration with citalopram may increase the plasma concentrations of clozapine. The mechanism may involve inhibition of the CYP450 2C19- and 2D6-mediated metabolism of clozapine, although citalopram has generally been considered a weak inhibitor of CYP450 isoenzymes. In one case report, a 39-year-old patient with schizoaffective disorder treated with clozapine (400 mg/day) developed evidence of clozapine toxicity shortly after the addition of citalopram (20 mg/day initially, then increased to 40 mg/day). Sedation, fatigue, enuresis, hypersalivation, and confusion occurred in association with elevated serum concentrations of clozapine and norclozapine. Clozapine levels decreased and adverse reactions resolved within 2 weeks after citalopram dosage was reduced to 20 mg/day.

MANAGEMENT: Pharmacologic response and serum clozapine concentrations should be monitored more closely following initiation, discontinuation or change of dosage of citalopram in patients who are stabilized on their antipsychotic regimen, and the clozapine dosage adjusted as necessary.

References
  • "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.
  • "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  • Borba CP, Henderson DC "Citalopram and clozapine: Potential drug interaction." J Clin Psychiatry 61 (2000): 301-2
Celexa (Citalopram Tablets)

Generic Name: citalopram

Brand name: Celexa

Synonyms: Celexa

Clozaril

Generic Name: clozapine

Brand name: Clozaril, Fazaclo, Versacloz, Clopine, CloZAPine Synthon, Denzapine, Zaponex

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle